Artur Racewicz

2.6k total citations · 1 hit paper
14 papers, 1.5k citations indexed

About

Artur Racewicz is a scholar working on Immunology, Rheumatology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Artur Racewicz has authored 14 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Immunology, 7 papers in Rheumatology and 6 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Artur Racewicz's work include Biosimilars and Bioanalytical Methods (8 papers), Rheumatoid Arthritis Research and Therapies (7 papers) and Pharmaceutical studies and practices (6 papers). Artur Racewicz is often cited by papers focused on Biosimilars and Bioanalytical Methods (8 papers), Rheumatoid Arthritis Research and Therapies (7 papers) and Pharmaceutical studies and practices (6 papers). Artur Racewicz collaborates with scholars based in Poland, United States and South Korea. Artur Racewicz's co-authors include Sunil Agarwal, Nicole F. Li, Anna Filipowicz‐Sosnowska, Paul Emery, Ronald van Vollenhoven, L Szczepański, Roy Fleischmann, Joy Schechtman, Arthur Kavanaugh and E. Hessey and has published in prestigious journals such as Annals of the Rheumatic Diseases, Bone and Osteoporosis International.

In The Last Decade

Artur Racewicz

13 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trial

2006 783 citations Paul Emery, Roy Fleischmann et al. Arthritis & Rheumatism profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Artur Racewicz Poland	9	933	660	344	325	304	14	1.5k
William Shergy United States	19	1.2k 1.3×	561 0.8×	300 0.9×	274 0.8×	481 1.6×	24	1.9k
Piotr Leszczyński Poland	20	914 1.0×	813 1.2×	108 0.3×	295 0.9×	269 0.9×	70	1.5k
Joy Schechtman United States	11	1.1k 1.1×	533 0.8×	360 1.0×	405 1.2×	421 1.4×	17	1.7k
E. Hessey United Kingdom	6	1.7k 1.8×	732 1.1×	710 2.1×	615 1.9×	650 2.1×	8	2.4k
J Jäger Australia	3	1.2k 1.3×	294 0.4×	255 0.7×	120 0.4×	577 1.9×	5	1.4k
T. Li United States	6	769 0.8×	380 0.6×	173 0.5×	237 0.7×	281 0.9×	6	1.0k
G. M. Bartelds Netherlands	13	978 1.0×	1.0k 1.5×	323 0.9×	714 2.2×	334 1.1×	15	1.9k
J. Box United States	7	763 0.8×	367 0.6×	217 0.6×	204 0.6×	356 1.2×	10	1.1k
Charles Ludivico United States	9	741 0.8×	268 0.4×	228 0.7×	103 0.3×	352 1.2×	13	1.0k
Oscar G. Segurado United States	17	455 0.5×	412 0.6×	67 0.2×	88 0.3×	229 0.8×	43	1.1k

Countries citing papers authored by Artur Racewicz

Since Specialization

Citations

This map shows the geographic impact of Artur Racewicz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Artur Racewicz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Artur Racewicz more than expected).

Fields of papers citing papers by Artur Racewicz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Artur Racewicz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Artur Racewicz. The network helps show where Artur Racewicz may publish in the future.

Co-authorship network of co-authors of Artur Racewicz

This figure shows the co-authorship network connecting the top 25 collaborators of Artur Racewicz. A scholar is included among the top collaborators of Artur Racewicz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Artur Racewicz. Artur Racewicz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Burmester, Gerd R, Artur Racewicz, Janusz Jaworski, et al.. (2025). Efficacy and Safety of Biosimilar CT-P47 Versus Reference Tocilizumab: 1-Year Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study in Patients with Rheumatoid Arthritis. Clinical Drug Investigation. 45(8). 551–563.

Smolen, Josef S, Artur Racewicz, Janusz Jaworski, et al.. (2024). Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47. RMD Open. 10(4). e004514–e004514. 3 indexed citations

Weinblatt, Michael E., Asta Baranauskaitė, Eva Dokoupilová, et al.. (2018). Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis. Arthritis & Rheumatology. 70(6). 832–840. 101 indexed citations

Weinblatt, Michael E., Asta Baranauskaitė, Jaroslaw Niebrzydowski, et al.. (2017). Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis. Arthritis & Rheumatology. 70(1). 40–48. 110 indexed citations

Yoo, Dae‐Hyun, Artur Racewicz, Jan Brzezicki, et al.. (2016). A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Research & Therapy. 18(1). 82–82. 137 indexed citations

Weinblatt, Michael E., Asta Baranauskaitė, Jaroslaw Niebrzydowski, et al.. (2016). FRI0161 Sustained Efficacy and Comparable Safety and Immunogenicity after Transition To SB5 (An Adalimumab Biosimilar) vs Continuation of The Adalimumab Reference Product in Patients with Rheumatoid Arthritis: Result of Phase III Study. Annals of the Rheumatic Diseases. 75. 487–487. 7 indexed citations

Baranauskaitė, Asta, Jaroslaw Niebrzydowski, Eva Dokoupilová, et al.. (2016). Sustained Efficacy and Comparable Safety and Immunogenicity after Transition to SB5 (an Adalimumab Biosimilar) Vs. Continuation of SB5 or Reference Adalimumab (Humira®) in Patients with Rheumatoid Arthritis: Results of Phase III Study. 3 indexed citations

Yoo, Dae‐Hyun, Artur Racewicz, Jan Brzezicki, et al.. (2013). OP0068 A Phase 3 Randomised Controlled Trial to Compare CT-P13 with Infliximab in Patients with Active Rheumatoid Arthritis: 54 Week Results from the Planetra Study. Annals of the Rheumatic Diseases. 72. A73–A73. 21 indexed citations

McClung, Michael R., José Zanchetta, Artur Racewicz, et al.. (2012). Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data. Osteoporosis International. 24(1). 293–299. 21 indexed citations

10.

Emery, P., Atul Deodhar, William F. C. Rigby, et al.. (2010). Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Annals of the Rheumatic Diseases. 69(9). 1629–1635. 253 indexed citations

11.

Ste‐Marie, Louis‐Georges, et al.. (2009). Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: A phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study. Clinical Therapeutics. 31(2). 272–285. 17 indexed citations

12.

Delmas, Pierre D., Michael R. McClung, José Zanchetta, et al.. (2007). Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone. 42(1). 36–42. 66 indexed citations

13.

Racewicz, Artur, et al.. (2007). Monthly dosing with risedronate 50 mg on three consecutive days a month compared with daily dosing with risedronate 5 mg: a 6-month pilot study. Current Medical Research and Opinion. 23(12). 3079–3089. 4 indexed citations

14.

Emery, Paul, Roy Fleischmann, Anna Filipowicz‐Sosnowska, et al.. (2006). The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trial. Arthritis & Rheumatism. 54(5). 1390–1400. 783 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact